Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator.
It is though that the clot-specific activity of tissue plasminogen activator, used in the treatment of acute myocardial infarction, makes bleeding complications less common than does the use of either streptokinase or urokinase. The incidence of intracerebral hemorrhage complicating the use of tissue plasminogen activator has been estimated to be 0.68%. This is a report of the rupture of an intracranial arteriovenous malformation complicating the use of tissue plasminogen activator therapy. Theories for the mechanism of hemorrhage in this instance are presented, as are suggestions for future use of the enzyme.
Proner
J
J
Department of Internal Medicine, New Rochelle Hospital Medical Center, NY.
Rosenblum
B R
BR
Rothman
A
A
D000368:Aged; D001921:Brain / Q000000981:diagnostic imaging; D002543:Cerebral Hemorrhage / Q000000981:diagnostic imaging / Q000209:etiology; D006429:Hemiplegia / Q000000981:diagnostic imaging / Q000209:etiology; D006801:Humans; D002538:Intracranial Arteriovenous Malformations / Q000150:complications* / Q000000981:diagnostic imaging; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy; D012422:Rupture, Spontaneous / Q000150:complications / Q000000981:diagnostic imaging; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed
D010959:Tissue Plasminogen Activator